Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (PBH) Market Cap

Prestige Consumer Healthcare Inc. has a market capitalization of $2.77B.

Financials based on reported quarter end 2025-12-31

Price: $57.52

-1.16 (-1.98%)

Market Cap: 2.77B

NYSE · time unavailable

CEO: Ronald Lombardi

Sector: Healthcare

Industry: Medical - Distribution

IPO Date: 2005-02-10

Website: https://www.prestigebrands.com

Prestige Consumer Healthcare Inc. (PBH) - Company Information

Market Cap: 2.77B · Sector: Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Analyst Sentiment

70%
Buy

Based on 17 ratings

Analyst 1Y Forecast: $68.50

Average target (based on 3 sources)

Consensus Price Target

Low

$66

Median

$66

High

$66

Average

$66

Potential Upside: 14.7%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PRESTIGE CONSUMER HEALTHCARE INC (PBH) — Investment Overview

🧩 Business Model Overview

Prestige Consumer Healthcare Inc. (PBH) operates as a consumer health and wellness products company, focusing on over-the-counter (OTC) healthcare solutions primarily across North America. The company specializes in acquiring, managing, and growing established brands in categories such as oral care, women’s health, eye and ear care, gastrointestinal health, and analgesics. PBH adopts an asset-light model by outsourcing manufacturing while maintaining control over brand management, marketing, supply chain logistics, and product innovation. The company is well-recognized for its disciplined approach to brand stewardship and its ability to revitalize and extend the lifecycle of acquired OTC brands, making it a consolidator of choice within the fragmented consumer healthcare sector.

💰 Revenue Streams & Monetisation Model

PBH’s primary revenue streams are derived from the sale of OTC healthcare products under well-known brands such as Dramamine, Monistat, Clear Eyes, Goody’s, BC Powder, and others. The company’s products are distributed through a broad network including mass merchandisers, drugstores, supermarkets, e-commerce platforms, and wholesale distributors. PBH’s monetisation model centers on value extraction from established, resilient brands with strong consumer recognition. This approach enables stable cash flow generation, supported by recurring consumer demand and channel partnerships. PBH emphasizes operational efficiency, pricing power, and targeted marketing to optimize revenue and margins. Incremental revenues may also be generated from periodic new product introductions and line extensions within existing brand families.

🧠 Competitive Advantages & Market Positioning

Several factors underpin Prestige Consumer Healthcare’s competitive advantage: - **Brand Portfolio Strength:** The company owns a portfolio of enduring, trusted brands that command significant market share in their respective categories. - **Category Focus & Niche Leadership:** Prestige often operates in “niche” OTC categories that are overlooked by larger pharmaceutical conglomerates, resulting in less direct competition and attractive shelf-space economics. - **Operational Discipline:** With a lean corporate structure and robust supply chain management, PBH maintains high margins and operational flexibility. - **M&A Expertise:** The company’s proven ability to identify, acquire, and integrate non-core or underinvested brands from larger players enables continuous portfolio strengthening. - **Stable Channel Relationships:** Prestige has deep-rooted relationships with leading retailers, allowing for prime product placement and strong sell-through. - **Regulatory & Consumer Trust:** The regulatory hurdle for OTC healthcare, especially for legacy brands, creates a moderate moat against new entrants, while established consumer trust supports repeat purchases.

🚀 Multi-Year Growth Drivers

Prestige Consumer Healthcare’s multi-year growth trajectory is supported by several secular and company-specific factors: - **Demographic Trends:** An aging population and increased consumer focus on self-care drive secular demand for OTC health products. - **Shift Toward Self-Medication:** Rising healthcare costs and preference for accessible remedies support ongoing growth in the consumer healthcare sector. - **Brand Acquisition Pipeline:** Ample opportunity remains for PBH to further consolidate the fragmented OTC landscape by acquiring incremental brands that can be revitalized. - **International Expansion:** Although predominantly North American, PBH has room to leverage existing brands and expertise in international markets, offering a runway for geographic growth. - **Product Innovation:** The company continues to invest in line extensions, formulation improvements, and packaging innovations to address evolving consumer preferences. - **Margin Expansion:** Ongoing initiatives in supply chain optimization and SKU rationalization may drive further efficiency gains and enhance profitability.

⚠ Risk Factors to Monitor

PBH’s investment thesis carries several risks worth continued attention: - **Acquisition Integration:** Successful integration of acquired brands is essential; missteps can lead to operational disruption and margin compression. - **Channel Risks:** Changes in retailer shelf space allocation, private label encroachment, and distributor consolidation could pressure sales volumes. - **Regulatory Landscape:** Although established OTC brands are less exposed to abrupt regulatory shifts, changes in labeling, ingredient standards, or registration requirements could impact certain product lines. - **Consumer Preferences:** Evolving consumer health trends and reputational shifts can affect brand relevancy and pricing power over time. - **Leverage & Balance Sheet:** PBH’s acquisition strategy often involves debt financing; elevated leverage may increase financial risk, especially if macroeconomic conditions tighten. - **Competition:** While PBH often operates in less-contested niche categories, competitive intensity can increase, particularly from both branded and private label entrants.

📊 Valuation & Market View

PBH is typically valued relative to other mid-cap consumer healthcare peers, using multiples such as forward EV/EBITDA, P/E, and free cash flow yield. Its asset-light model, stable cash flow generation, and predictable demand profile often command a modest premium versus generic or commoditized consumer businesses. The market tends to reward PBH’s disciplined capital allocation, focus on deleveraging, and consistent execution against acquisition and integration milestones. Sensitivity analyses within the investment community often center on potential returns on future acquisitions, success in maintaining margin structure, and ability to deliver incremental growth in mature product categories.

🔍 Investment Takeaway

Prestige Consumer Healthcare Inc. presents a compelling case as a consolidator and steward of established OTC healthcare brands in North America. Its asset-light, brand-focused model enables high returns on invested capital, reliable cash flow generation, and resilience to economic cycles. Multi-year secular tailwinds, synergistic acquisitions, and operational discipline support stable to moderate growth, with upside potential from further portfolio expansion and international opportunities. Investors should remain mindful of integration risks, evolving retail dynamics, and leverage considerations, but PBH’s business fundamentals and market positioning are robust. For long-term investors seeking exposure to the resilient and steadily growing consumer healthcare segment, PBH stands out as a consistent, cash-generative holding aligned with durable consumer health trends.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For the fiscal year ending December 31, 2025, PBH reported a revenue of $283.44M and a net income of $46.70M, translating to an earnings per share of $0.98. The company’s operating cash flow was robust at $78.29M, leading to a free cash flow of $75.26M. PBH’s balance sheet reveals total assets of $3.49B against total liabilities of $1.67B, indicating solid equity of $1.83B. Net debt stands at $1.02B, indicating moderate leverage. Despite these strong fundamentals, PBH's stock price has decreased by 27.37% over the past year, reflecting a challenging market environment. Analysts maintain a price target consensus of $66, aligning closely with the current price of $62, suggesting potential upside. The absence of dividends recently may deter income-focused investors, although the company's capability for shareholder returns is noteworthy due to its free cash flow. Overall, while PBH demonstrates good revenue and cash flow health, current market performance poses significant investment risks."

Revenue Growth

Neutral

The revenue of $283.44M indicates a steady growth trajectory but lacks exceptional performance.

Profitability

Positive

Net income stands at $46.70M, reflecting a healthy profitability margin.

Cash Flow Quality

Good

Strong operating cash flow of $78.29M and positive free cash flow highlight efficient cash management.

Leverage & Balance Sheet

Positive

A solid equity base with manageable net debt levels signals financial stability.

Shareholder Returns

Fair

Lack of recent dividends and a decline in stock price present challenges for shareholder returns.

Analyst Sentiment & Valuation

Neutral

Analyst price targets suggest potential for recovery, yet the current stock performance raises caution.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management sounded confident on the base business and cash generation, but the Q&A revealed the real issue is not demand collapse—it’s volatile retailer order patterns and the slow mechanical recovery of Clear Eyes supply. Q3 revenue of $283.4M beat forecast slightly, with adjusted EPS $1.14 and YTD free cash flow of $209M (+13%). However, Q4 guidance was framed as “lower end of the prior range” due to what retailers did with orders after Q3 volatility, including inventory-style destocking/adjusted ordering rather than consumption weakening. The eye-care recovery is progressing sequentially, yet restocking to full SKU breadth was explicitly pushed into fiscal 2027 (not a switch). Christine also disclosed a discrete ~$10M supplier-loan write-off after an unusual supplier shutdown, underscoring execution/continuity risks. Overall tone: optimistic about long-term algorithms; analyst pressure focused on timing (when inventory normalizes) and margin risk—management said margins should remain relatively stable, but visibility is constrained by supply ramp and channel behavior.

AI IconGrowth Catalysts

  • Sequential improvement in Clear Eyes supply (2nd quarter in a row) with expectation of further improvement through Q4 2026 and beyond
  • Ability to diversify pressure runs/SKUs once production ramps (currently focused on top two items: Redness Relief and Max Redness)
  • Marketing acceleration as Clear Eyes production becomes more consistent/available
  • E-commerce consumption grew >10% in Q3

Business Development

  • Acquired strategic partner Pillar Five in December (~$110M closure cost referenced in Q3)
  • Brought on two new third-party suppliers for Clear Eyes over the last nine months (near-term production + long-term backup)
  • Extended ~$8M financial assistance (supplier loan) to a struggling supplier to preserve continuity of supply until product transfer was completed

AI IconFinancial Highlights

  • Q3 revenue: $283.4M, down 2.4% YoY (down 2.2% excluding FX); slightly better than forecast (management said sales were slightly better than forecast)
  • Adjusted diluted EPS: $1.14 vs $1.22 prior year (down slightly); Q3 gross margin: 55.5% (in line with expectations)
  • Free cash flow: $209M year-to-date; up 13% YoY
  • Adjusted EBITDA margin remained in the low 30s (no specific bps given)
  • Q3 included an approximate $10M write-off of a supplier loan (secured by supplier assets; recovery expected but amount not estimable)
  • First nine months: total company gross margin 55.7%, up 50 bps YoY
  • Full-year gross margin outlook: 57% adjusted gross margin in Q4
  • FY 2026 tariff outlook unchanged at approx. $5M
  • Full-year A&M spend rate: just under 14% of sales (vs 14.1% for first nine months)
  • Full-year G&A: just over 10% of sales
  • FY EPS narrowed to ~ $4.54 adjusted diluted EPS

AI IconCapital Funding

  • Share repurchases in Q3: ~$46M (during the quarter)
  • Year-to-date repurchases: >$150M (nearly 5% of shares outstanding)
  • Net debt at Dec 31: approx. $1B; covenant-defined leverage ratio 2.6x
  • FY 2026 free cash flow outlook maintained: $245M or more

AI IconStrategy & Ops

  • Clear Eyes supply actions: (1) added two new third-party suppliers (2) Pillar Five acquisition for direct control of a supply-chain element (3) installed a new high-speed line beginning in December
  • Pillar Five expected capability to support majority of eye care production internally over time; ramp is not a switch—restocking timing expected through fiscal 2027
  • Expected one-time investment as Pillar Five transitions from private ownership
  • Marketing/funding plan: shifted advertising/marketing focus rather than taking down total A&M; expected some increase in Clear Eyes marketing activity as supply returns without meaningful P&L profile impact
  • Supply constraint noted as driver of lower eye/ear sales and year-to-date declines

AI IconMarket Outlook

  • FY 2026 sales outlook narrowed to ~ $1.1B revenue
  • Q4 outlook: sequential improvement in Clear Eyes supply (3 consecutive quarters of improvement) and guidance built around observed Q3 retailer order-pattern volatility
  • Q4 assumptions (from prepared remarks): interest expense ~$11M, normalized tax rate ~24%, share count just under 48M
  • Full-year free cash flow maintained: $245M or more
  • Next detailed update: May call (for fiscal 2027 puts/takes and further Clear Eyes supply color)

AI IconRisks & Headwinds

  • Clear Eyes supply constraints leading to lower eye and ear care category sales in Q3 and anticipated impact in first nine months
  • Analyst-referenced consumer/channels volatility: shoppers changing where they shop; retailers/channels with headwinds adjusting order patterns (management confirmed it was more order-pattern/inventory destocking than consumption collapse)
  • Macro/turbulence mentioned: tariff inflation, government shutdown, public announcements related to acetaminophen
  • Analgesics category disruption: management cited acetaminophen-related announcements (Aldon) in early Q3; other big brands down as much as 15%; PBH down a couple of points
  • Lice incident levels down YoY (behind; will remain behind in Q4)
  • Supplier loan write-off risk materialized: approx. $10M written off when the partner shut down in December (recovery not quantified)

Sentiment: MIXED

Note: This summary was synthesized by AI from the PBH Q3 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PBH)

© 2026 Stock Market Info — Prestige Consumer Healthcare Inc. (PBH) Financial Profile